IRIX Stock Forecast: IRIDEX Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for IRIDEX Corp. is $2. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores IRIDEX Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (74): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IRIX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IRIX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2024 | Stifel | Maintains | Hold | $2.00 |
| 26 Aug 2022 | Stifel | Downgrade | Hold | — |
| 12 May 2021 | Roth Capital | Maintains | Buy | — |
| 3 Mar 2021 | Roth Capital | Maintains | Buy | — |
| 13 Jan 2021 | Roth Capital | Maintains | Buy | — |
| 12 May 2020 | Stifel | Maintains | Buy | — |
| 4 Jan 2019 | Stifel | Maintains | Buy | — |
| 4 Jan 2019 | Stifel Nicolaus | Maintains | Buy | — |
| 26 Oct 2018 | Stifel | Initiates | Buy | — |
| 26 Oct 2018 | Stifel Nicolaus | Initiates | Buy | — |
| 21 Dec 2016 | Roth Capital | Initiates | Buy | — |
| 26 Jan 2016 | Singular Research | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IRIX.
This page is one stock. Monday covers all of them.
IRIX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IRIX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, IRIDEX Corp. returned −52.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IRIX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.2×
- Price / book
- 2.3×
- EV / EBITDA
- —
Cheaper than 92% of US stocks
Cheaper than 39% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 34.2%
- Operating margin
- −5.1%
- Net margin
- −6.9%
Higher than 41% of US stocks
Higher than 30% of US stocks
Higher than 23% of US stocks
- Return on equity
- −92.4%
- Return on assets
- −5.5%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 32% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IRIDEX Corp. has a market value of $8.3M and an enterprise value of $18.0M.
Revenue in the twelve months to 30 June 2026: $51.6M. The latest quarter shrank 7.4% year on year.
Net income over the same four quarters: −$3.5M, a −6.9% net margin.
Diluted earnings per share, trailing twelve months: −$0.20.
Free cash flow in the twelve months to 30 June 2026: −$2.0M.
IRIDEX Corp. employs 93 people — $555K of revenue per employee.
Data provided by Twelve Data
IRIX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IRIX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own IRIDEX Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IRIX
What is the IRIX stock price forecast for 2026-2027?
The median 12-month analyst price target for IRIDEX Corp. is $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IRIX stock a buy right now?
Of the 1 analyst covering IRIDEX Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRIDEX Corp. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IRIX?
As at 21 Nov 2026, IRIDEX Corp. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (74 of 100).
Will IRIX stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $2, and Ticker Nerd's factor model ranks IRIDEX Corp. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IRIX stock forecast for 2030?
No analyst covering IRIDEX Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
How has IRIX stock performed over the past year?
IRIDEX Corp. returned -52.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does IRIDEX Corp. do?
Iridex Corp. is an ophthalmic medical technology company that develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for eye care professionals. The company’s products are used in the treatment of glaucoma, retinal disorders, diabetic eye disease, and other sight-threatening conditions, supporting both office-based procedures and surgical settings.
About IRIDEX Corp.
Iridex Corp. is an ophthalmic medical technology company that develops, manufactures, and markets laser-based medical systems, delivery devices, and consumable instrumentation for eye care professionals. The company’s products are used in the treatment of glaucoma, retinal disorders, diabetic eye disease, and other sight-threatening conditions, supporting both office-based procedures and surgical settings. Iridex’s portfolio includes laser consoles, delivery platforms, and single-use probes designed to work with its proprietary MicroPulse technology and other treatment systems. The company serves ophthalmologists, hospitals, surgical centers, research institutions, veterinary practices, and clinics through direct sales in the United States and distributor networks internationally. Headquartered in Mountain View, California, and founded in 1989, Iridex plays a specialized role in the medical device market by providing tools focused on precision ophthalmic therapy and recurring consumable use.
CEO Mr. Patrick Mercer · 93 employees · United States · https://www.iridex.com